Skip to main content
Premium Trial:

Request an Annual Quote

Genewiz to Acquire Beckman Coulter's Genomic Services Business

NEW YORK (GenomeWeb) – Genomics service provider Genewiz said today that it has agreed to acquire Beckman Coulter's genomic services business.

The deal's financial terms were not disclosed. It has been approved by both boards and will close immediately, Genewiz added.

Beckman Coulter's genomic service business provides sequencing services — including comprehensive Sanger sequencing, next-generation sequencing, bioinformatics, and CLIA and clinical services — to healthcare businesses, academia, and government institutions. Genewiz chairman and CEO Steve Sun praised the deal in a statement today, saying the acquisition "is an ideal fit with Genewiz's global strategy and expansion plans."

Beckman Coulter's genomics services business has proven its leadership role in the market, Sun added, and its experts "have built an efficient workflow that allows for the delivery of quality and timely results to its customers. The integration of these two businesses will allow for an increased level of service and value to customers worldwide." 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.